Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd is an established drug development company in the biopharmaceutical industry, with a proven track record of producing effective anti-SARS-CoV-2 antibodies. The company's lead product, PEMGARDA, has received emergency use authorization and is approved for moderate to severely immunocompromised patients. The company's next-generation antibody, VYD2311, is in a Phase 3 clinical trial with pivotal data expected by the end of 2026, and it has shown data suggesting superior levels of protection compared to current mRNA vaccines. Additionally, management is actively in dialogue with the FDA for potential accelerated approval of PEMGARDA, and the company retains a full year of runway to complete these discussions. With enrollment complete and enough events recorded to power a positive result at the top end of efficacy expectations, Invivyd's next-generation antibody VYD2311 is the main value driver for the company. We value Invivyd using a DCF analysis with a 17.0% discount rate and a 1.0% terminal growth rate, and see the potential risks for the company as being standard for the biopharmaceutical industry.

Invivyd is heavily focused on the development and commercialization of its lead product PEMGARDA, which has shown high efficacy in protecting immunocompromised individuals from COVID-19. However, the company's financials may be impacted by the growing cost of COVID-19 treatment and the emergence of new hotspots, which could delay or hinder the progress of its ongoing clinical trials. Additionally, Invivyd's LIBERTY trial, while promising, is not expected to release topline data until 3Q26, which may be too late in the race against other COVID-19 treatments and vaccines in the market. Overall, while Invivyd has potential in the biopharmaceutical industry, the company's heavy focus on COVID-19 may also make it vulnerable to fluctuations and challenges in this particular market.